JP2018168170A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018168170A5 JP2018168170A5 JP2018111869A JP2018111869A JP2018168170A5 JP 2018168170 A5 JP2018168170 A5 JP 2018168170A5 JP 2018111869 A JP2018111869 A JP 2018111869A JP 2018111869 A JP2018111869 A JP 2018111869A JP 2018168170 A5 JP2018168170 A5 JP 2018168170A5
- Authority
- JP
- Japan
- Prior art keywords
- acid
- composition
- alcohol
- compound
- cis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 56
- 150000001875 compounds Chemical class 0.000 claims 33
- 150000002191 fatty alcohols Chemical class 0.000 claims 23
- 125000003700 epoxy group Chemical group 0.000 claims 19
- 102000001708 Protein Isoforms Human genes 0.000 claims 16
- 108010029485 Protein Isoforms Proteins 0.000 claims 16
- 102000003923 Protein Kinase C Human genes 0.000 claims 16
- 108090000315 Protein Kinase C Proteins 0.000 claims 16
- 235000014113 dietary fatty acids Nutrition 0.000 claims 13
- 229930195729 fatty acid Natural products 0.000 claims 13
- 239000000194 fatty acid Substances 0.000 claims 13
- LVZWSLJZHVFIQJ-UHFFFAOYSA-N Cyclopropane Chemical compound C1CC1 LVZWSLJZHVFIQJ-UHFFFAOYSA-N 0.000 claims 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 12
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 claims 12
- 229950011148 cyclopropane Drugs 0.000 claims 10
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 10
- GVNVAWHJIKLAGL-UHFFFAOYSA-N 2-(cyclohexen-1-yl)cyclohexan-1-one Chemical compound O=C1CCCCC1C1=CCCCC1 GVNVAWHJIKLAGL-UHFFFAOYSA-N 0.000 claims 8
- 101150065749 Churc1 gene Proteins 0.000 claims 8
- 102100038239 Protein Churchill Human genes 0.000 claims 8
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 claims 8
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 8
- -1 fatty acid esters Chemical class 0.000 claims 7
- 150000004665 fatty acids Chemical class 0.000 claims 7
- YUFFSWGQGVEMMI-JLNKQSITSA-N (7Z,10Z,13Z,16Z,19Z)-docosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCCCC(O)=O YUFFSWGQGVEMMI-JLNKQSITSA-N 0.000 claims 6
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 claims 6
- 235000021294 Docosapentaenoic acid Nutrition 0.000 claims 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 6
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 claims 6
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 claims 6
- 235000020669 docosahexaenoic acid Nutrition 0.000 claims 6
- 229940090949 docosahexaenoic acid Drugs 0.000 claims 6
- 235000020673 eicosapentaenoic acid Nutrition 0.000 claims 6
- 229960005135 eicosapentaenoic acid Drugs 0.000 claims 6
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 claims 6
- 230000004770 neurodegeneration Effects 0.000 claims 6
- 229940055577 oleyl alcohol Drugs 0.000 claims 6
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 claims 6
- TWSWSIQAPQLDBP-CGRWFSSPSA-N (7e,10e,13e,16e)-docosa-7,10,13,16-tetraenoic acid Chemical compound CCCCC\C=C\C\C=C\C\C=C\C\C=C\CCCCCC(O)=O TWSWSIQAPQLDBP-CGRWFSSPSA-N 0.000 claims 4
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 claims 4
- IKYKEVDKGZYRMQ-PDBXOOCHSA-N (9Z,12Z,15Z)-octadecatrien-1-ol Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCCO IKYKEVDKGZYRMQ-PDBXOOCHSA-N 0.000 claims 4
- 235000021292 Docosatetraenoic acid Nutrition 0.000 claims 4
- 230000003213 activating effect Effects 0.000 claims 4
- TWSWSIQAPQLDBP-UHFFFAOYSA-N adrenic acid Natural products CCCCCC=CCC=CCC=CCC=CCCCCCC(O)=O TWSWSIQAPQLDBP-UHFFFAOYSA-N 0.000 claims 4
- 235000020661 alpha-linolenic acid Nutrition 0.000 claims 4
- 235000021342 arachidonic acid Nutrition 0.000 claims 4
- 229940114079 arachidonic acid Drugs 0.000 claims 4
- 229960004488 linolenic acid Drugs 0.000 claims 4
- QYDYPVFESGNLHU-KHPPLWFESA-N methyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC QYDYPVFESGNLHU-KHPPLWFESA-N 0.000 claims 4
- 150000002148 esters Chemical class 0.000 claims 3
- CCPPLLJZDQAOHD-BEBBCNLGSA-N (-)-vernolic acid Chemical compound CCCCC[C@@H]1O[C@@H]1C\C=C/CCCCCCCC(O)=O CCPPLLJZDQAOHD-BEBBCNLGSA-N 0.000 claims 2
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 claims 2
- DPUOLQHDNGRHBS-UHFFFAOYSA-N Brassidinsaeure Natural products CCCCCCCCC=CCCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-UHFFFAOYSA-N 0.000 claims 2
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 claims 2
- URXZXNYJPAJJOQ-UHFFFAOYSA-N Erucic acid Natural products CCCCCCC=CCCCCCCCCCCCC(O)=O URXZXNYJPAJJOQ-UHFFFAOYSA-N 0.000 claims 2
- 208000019022 Mood disease Diseases 0.000 claims 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 2
- YHVNLORIIDPMPQ-RRABGKBLSA-N cyclopropane;(e)-octadec-9-enoic acid Chemical compound C1CC1.CCCCCCCC\C=C\CCCCCCCC(O)=O YHVNLORIIDPMPQ-RRABGKBLSA-N 0.000 claims 2
- VCDLWFYODNTQOT-UHFFFAOYSA-N docosahexaenoic acid methyl ester Natural products CCC=CCC=CCC=CCC=CCC=CCC=CCCC(=O)OC VCDLWFYODNTQOT-UHFFFAOYSA-N 0.000 claims 2
- IQLUYYHUNSSHIY-HZUMYPAESA-N eicosatetraenoic acid Chemical compound CCCCCCCCCCC\C=C\C=C\C=C\C=C\C(O)=O IQLUYYHUNSSHIY-HZUMYPAESA-N 0.000 claims 2
- QYDYPVFESGNLHU-UHFFFAOYSA-N elaidic acid methyl ester Natural products CCCCCCCCC=CCCCCCCCC(=O)OC QYDYPVFESGNLHU-UHFFFAOYSA-N 0.000 claims 2
- DPUOLQHDNGRHBS-KTKRTIGZSA-N erucic acid Chemical compound CCCCCCCC\C=C/CCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-KTKRTIGZSA-N 0.000 claims 2
- 229940098330 gamma linoleic acid Drugs 0.000 claims 2
- VZCCETWTMQHEPK-UHFFFAOYSA-N gamma-Linolensaeure Natural products CCCCCC=CCC=CCC=CCCCCC(O)=O VZCCETWTMQHEPK-UHFFFAOYSA-N 0.000 claims 2
- VZCCETWTMQHEPK-QNEBEIHSSA-N gamma-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O VZCCETWTMQHEPK-QNEBEIHSSA-N 0.000 claims 2
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 claims 2
- LUYYTKKXYNRVHQ-TYYHYDAASA-N methyl (2e,4e,6e,8e,10e,12e)-docosa-2,4,6,8,10,12-hexaenoate Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(=O)OC LUYYTKKXYNRVHQ-TYYHYDAASA-N 0.000 claims 2
- JTSVQVYMBXVLFI-IPASSIEDSA-N methyl (z)-11-[(2r,3s)-3-pentyloxiran-2-yl]undec-9-enoate Chemical compound CCCCC[C@@H]1O[C@@H]1C\C=C/CCCCCCCC(=O)OC JTSVQVYMBXVLFI-IPASSIEDSA-N 0.000 claims 2
- 150000004702 methyl esters Chemical class 0.000 claims 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims 2
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 claims 2
- CCPPLLJZDQAOHD-UHFFFAOYSA-N vernolic acid Natural products CCCCCC1OC1CC=CCCCCCCCC(O)=O CCPPLLJZDQAOHD-UHFFFAOYSA-N 0.000 claims 2
- DVWSXZIHSUZZKJ-UHFFFAOYSA-N 18:3n-3 Natural products CCC=CCC=CCC=CCCCCCCCC(=O)OC DVWSXZIHSUZZKJ-UHFFFAOYSA-N 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- DVWSXZIHSUZZKJ-YSTUJMKBSA-N methyl linolenate Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(=O)OC DVWSXZIHSUZZKJ-YSTUJMKBSA-N 0.000 claims 1
- 235000021281 monounsaturated fatty acids Nutrition 0.000 claims 1
- 239000001294 propane Substances 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8417208P | 2008-07-28 | 2008-07-28 | |
| US61/084,172 | 2008-07-28 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016051212A Division JP6449186B2 (ja) | 2008-07-28 | 2016-03-15 | 神経変性疾患の治療のためのｐｋｃ活性化化合物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018168170A JP2018168170A (ja) | 2018-11-01 |
| JP2018168170A5 true JP2018168170A5 (enExample) | 2019-03-14 |
Family
ID=41136734
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011521235A Expired - Fee Related JP5653917B2 (ja) | 2008-07-28 | 2009-07-28 | 神経変性疾患の治療のためのｐｋｃ活性化化合物 |
| JP2014182597A Pending JP2015042643A (ja) | 2008-07-28 | 2014-09-08 | 神経変性疾患の治療のためのｐｋｃ活性化化合物 |
| JP2016051212A Expired - Fee Related JP6449186B2 (ja) | 2008-07-28 | 2016-03-15 | 神経変性疾患の治療のためのｐｋｃ活性化化合物 |
| JP2018111869A Pending JP2018168170A (ja) | 2008-07-28 | 2018-06-12 | 神経変性疾患の治療のためのｐｋｃ活性化化合物 |
Family Applications Before (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011521235A Expired - Fee Related JP5653917B2 (ja) | 2008-07-28 | 2009-07-28 | 神経変性疾患の治療のためのｐｋｃ活性化化合物 |
| JP2014182597A Pending JP2015042643A (ja) | 2008-07-28 | 2014-09-08 | 神経変性疾患の治療のためのｐｋｃ活性化化合物 |
| JP2016051212A Expired - Fee Related JP6449186B2 (ja) | 2008-07-28 | 2016-03-15 | 神経変性疾患の治療のためのｐｋｃ活性化化合物 |
Country Status (6)
| Country | Link |
|---|---|
| US (7) | US8163800B2 (enExample) |
| EP (3) | EP3586839A1 (enExample) |
| JP (4) | JP5653917B2 (enExample) |
| CA (2) | CA2731171C (enExample) |
| ES (1) | ES2683021T3 (enExample) |
| WO (1) | WO2010014585A1 (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090030055A1 (en) * | 2002-07-02 | 2009-01-29 | Thomas Nelson | PKC activation as a means for enhancing sAPPALPHA secretion and improving cognition using bryostatin type compounds |
| EP3586839A1 (en) | 2008-07-28 | 2020-01-01 | Blanchette Rockefeller Neurosciences, Institute | Pkc-activating compounds for the treatment of neurodegenerative diseases |
| AU2010313249B2 (en) | 2009-10-30 | 2016-05-19 | Biojiva Llc | Alleviating oxidative stress disorders with PUFA derivatives |
| WO2011102907A1 (en) * | 2010-02-22 | 2011-08-25 | Blanchette Rockefeller Neurosciences Institute | Alzheimer's disease-specific alterations of protein kinase c epsilon (pkc-epsilon) protein levels |
| US9107890B2 (en) | 2010-07-08 | 2015-08-18 | Blanchette Rockefeller Neurosciences Institute | PKC activators and anticoagulant in regimen for treating stroke |
| CA2808660A1 (en) | 2010-08-19 | 2012-02-23 | Blanchette Rockefeller Neurosciences Institute | Treatment of cognitive disorders associated with abnormal dendritic spines using pkc activators |
| KR102020611B1 (ko) | 2011-04-26 | 2019-09-10 | 레트로토프 인코포레이티드 | Ｐｕｆａ와 관련된 신경퇴행성 질환 및 근육 질환 |
| JP6145087B2 (ja) | 2011-04-26 | 2017-06-07 | レトロトップ、 インコーポレイテッドＲｅｔｒｏｔｏｐｅ， Ｉｎｃ． | Ｐｕｆａ酸化関与障害 |
| KR102110200B1 (ko) | 2011-04-26 | 2020-05-13 | 레트로토프 인코포레이티드 | 산화성 망막 질환 |
| KR102020579B1 (ko) | 2011-04-26 | 2019-09-10 | 레트로토프 인코포레이티드 | 에너지 프로세싱 손상 장애 및 미토콘드리아 결함 |
| US20140235496A1 (en) | 2011-10-05 | 2014-08-21 | Blanchette Rockefeller Neurosciences Drive | Stimulus-elicited genomic profile markers of a neurodegenerative condition |
| JP6422778B2 (ja) * | 2011-11-13 | 2018-11-14 | ブランシェット・ロックフェラー・ニューロサイエンスィズ・インスティテュート | Ｐｋｃアクチベーターおよびその組合せ |
| US9163032B2 (en) | 2011-11-13 | 2015-10-20 | Blanchette Rockefeller Neurosciences Insitute | Esters of DCPLA and methods of treatment using the same |
| WO2014126191A1 (ja) * | 2013-02-15 | 2014-08-21 | 株式会社西崎創薬研究所 | シクロプロパン環を有する不飽和脂肪酸誘導体を含むリン脂質化合物 |
| JP2016516201A (ja) * | 2013-03-15 | 2016-06-02 | ブランシェット・ロックフェラー・ニューロサイエンスィズ・インスティテュート | 神経保護性ｐｋｃ活性化因子を特定する方法 |
| ES2732153T3 (es) | 2013-10-18 | 2019-11-20 | Blanchette Rockefeller Neurosciences Inst | Esteres halogenados de ácidos grasos insaturados ciclopropanados para su utilización en el tratamiento de las enfermedades neurodegenerativas |
| KR20170031653A (ko) | 2014-04-18 | 2017-03-21 | 뉴로트롭 바이오싸이언스 인크. | 지질 축적 장애의 치료를 위한 방법 및 조성물 |
| US9413754B2 (en) | 2014-12-23 | 2016-08-09 | Airwatch Llc | Authenticator device facilitating file security |
| JP2018521113A (ja) | 2015-05-11 | 2018-08-02 | アルコン、ダニエル・エル． | ＡｐｏＥ４対立遺伝子の存在を決定した後のＰＫＣ活性化因子を使用した神経変性状態の治療 |
| WO2017053659A1 (en) | 2015-09-23 | 2017-03-30 | Khan Tapan K | Methods for survival and rejuvenation of dermal fibroblasts using pkc activators |
| WO2017062924A1 (en) | 2015-10-08 | 2017-04-13 | Alkon Daniel L | Dosing regimens of pkc activators |
| CN108698987B (zh) | 2015-11-23 | 2021-07-13 | 乐巢拓普有限公司 | 1,4-二烯体系的位点特异性同位素标记 |
| JP6912072B2 (ja) * | 2016-12-14 | 2021-07-28 | 国立大学法人山口大学 | 前頭側頭型認知症の予防又は治療用医薬 |
| WO2018187647A1 (en) | 2017-04-06 | 2018-10-11 | Neurotrope Bioscience, Inc. | Methods and compositions for treatment of neurological diseases, disorders, or conditions |
| EP3964210A1 (en) * | 2018-05-18 | 2022-03-09 | Neurotrope Bioscience, Inc. | Methods and compositions for treatment of alzheimer's disease |
| US20220023255A1 (en) * | 2018-12-07 | 2022-01-27 | The Johns Hopkins University | Methods, compositions and kits for treating multiple sclerosis and other disorders |
| KR20260018193A (ko) | 2020-02-21 | 2026-02-06 | 레트로토프 인코포레이티드 | 고도불포화 지방산 및 이의 유도체의 동위원소 변형을 위한 공정 |
| US20220133687A1 (en) * | 2020-11-02 | 2022-05-05 | Synaptogenix, Inc. | Methods of treating and preventing neurodegenerative diseases with hgf activating compounds |
| US12109194B2 (en) | 2021-02-05 | 2024-10-08 | Biojiva Llc | Synergistic combination therapy for treating ALS |
| US20240180869A1 (en) * | 2021-02-08 | 2024-06-06 | Synaptogenix, Inc. | Treatment of multiple sclerosis using pkc activators |
| US20240165075A1 (en) * | 2021-02-08 | 2024-05-23 | Synaptogenix, Inc. | Treatment of optic nerve inflammation using pkc activators |
| WO2023225073A1 (en) * | 2022-05-18 | 2023-11-23 | Virginia Commonwealth University | Methods for treatment of cognitive impairment in cirrhosis patients |
| WO2025056602A1 (en) | 2023-09-11 | 2025-03-20 | Elastin Biosciences Ltd. | Pharmaceutical compositions and use thereof in treatment of conditions and diseases related to elastin deficiency and/or aging |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6080784A (en) | 1986-06-11 | 2000-06-27 | Procyon Pharmaceuticals, Inc. | Protein kinase C modulators N |
| US5385915A (en) | 1990-05-16 | 1995-01-31 | The Rockefeller University | Treatment of amyloidosis associated with Alzheimer disease using modulators of protein phosphorylation |
| US5242932A (en) | 1991-12-17 | 1993-09-07 | The Rockefeller University | Treatment of amyloidosis associated with alzheimer disease |
| WO1993011231A1 (en) | 1991-12-06 | 1993-06-10 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Tools for the diagnosis and treatment of alzheimer's disease |
| US5766846A (en) | 1992-07-10 | 1998-06-16 | Athena Neurosciences | Methods of screening for compounds which inhibit soluble β-amyloid peptide production |
| JPH06279311A (ja) | 1993-03-26 | 1994-10-04 | Sagami Chem Res Center | プロテインキナーゼｃアイソザイムの活性化剤 |
| US6107050A (en) | 1993-05-03 | 2000-08-22 | The United States Of America As Represented By The Department Of Health And Human Services | Diagnostic test for alzheimers disease |
| US20030108956A1 (en) | 1993-05-03 | 2003-06-12 | Alkon Daniel L. | Cell tests for Alzheimer's disease |
| US5976816A (en) | 1993-05-03 | 1999-11-02 | The United States Of America As Represented By The Department Of Health And Human Services | Cell tests for alzheimer's disease |
| US7625697B2 (en) | 1994-06-17 | 2009-12-01 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for constructing subarrays and subarrays made thereby |
| US6017887A (en) | 1995-01-06 | 2000-01-25 | Sibia Neurosciences, Inc. | Peptide, peptide analog and amino acid analog protease inhibitors |
| US6303567B1 (en) | 1995-03-14 | 2001-10-16 | Praecis Pharmaceuticals, Inc . | Modulators of β-amyloid peptide aggregation comprising D-amino acids |
| US6001580A (en) | 1995-03-28 | 1999-12-14 | Takeda Chemical Industries, Inc. | Method for assaying ERK2 map kinase |
| US6277826B1 (en) | 1996-08-27 | 2001-08-21 | Praecis Pharmaceuticals, Inc. | Modulators of β-amyloid peptide aggregation comprising D-amino acids |
| WO1997032020A2 (en) | 1996-02-29 | 1997-09-04 | Mount Sinai Hospital Corporation | Shc proteins |
| JPH1090263A (ja) | 1996-07-25 | 1998-04-10 | Mclean Hospital Corp:The | アルツハイマー病の診断のためのｅｒｋ−１およびｅｒｋ−２の利用 |
| WO2000020867A1 (en) | 1998-10-01 | 2000-04-13 | Alexey Vladimirovich Titievsky | A novel ret-independent signaling pathway for gdnf |
| AU5150300A (en) | 1999-05-19 | 2000-12-05 | Mitokor | Differential gene expression in specific regions of the brain in neurodegenerative diseases |
| WO2001027624A2 (en) | 1999-10-08 | 2001-04-19 | Superarray, Inc. | Compositions and methods for detecting protein modification and enzymatic activity |
| US20030165481A1 (en) | 2000-02-24 | 2003-09-04 | Hersh Louis B. | Amyloid peptide inactivating enzyme to treat Alzheimer's disease |
| JP2003527604A (ja) | 2000-03-10 | 2003-09-16 | ワシントン・ユニバーシティ | 個々の細胞の標識方法 |
| JP2003528071A (ja) | 2000-03-23 | 2003-09-24 | エラン ファーマスーティカルズ インコーポレイテッド | アルツハイマー病治療用組成物および方法 |
| US6495540B2 (en) | 2000-03-28 | 2002-12-17 | Bristol - Myers Squibb Pharma Company | Lactams as inhibitors of A-β protein production |
| EP1268434A1 (en) | 2000-04-03 | 2003-01-02 | Bristol-Myers Squibb Pharma Company | Cyclic lactams as inhibitors of a-beta protein production |
| CA2404273A1 (en) | 2000-04-11 | 2001-10-18 | Bristol-Myers Squibb Pharma Company | Substituted lactams as inhibitors of a.beta. protein production |
| JP2004502665A (ja) | 2000-06-30 | 2004-01-29 | イーラン ファーマスーティカルズ、インコーポレイテッド | アルツハイマー病を治療する化合物 |
| EP1315971A2 (en) | 2000-07-31 | 2003-06-04 | The Regents of The University of California | Model for alzheimer's disease and other neurodegenerative diseases |
| ES2267853T3 (es) | 2000-12-13 | 2007-03-16 | Wyeth | Inhibidroes de sulfonamida heteriociclicos de la produccion de beta amiloides. |
| AUPR215700A0 (en) | 2000-12-19 | 2001-01-25 | Fujisawa Pharmaceutical Co., Ltd. | Carboxylic acid compound having cyclopropane ring |
| EP1390404A2 (en) | 2000-12-21 | 2004-02-25 | Novartis AG | Interleukin-1 related gene and protein |
| CA2437497A1 (en) | 2001-02-06 | 2002-08-15 | Incyte Genomics, Inc. | Lipid-associated molecules |
| ATE394115T1 (de) | 2001-02-27 | 2008-05-15 | Brni Neurosciences Inst | Diagnose der alzheimer-krankheit auf basis von mitogenaktivierter proteinkinase-phosphorylierung |
| JP4024554B2 (ja) | 2001-02-27 | 2007-12-19 | 松下電器産業株式会社 | 燃料電池発電システム |
| US6874208B2 (en) | 2001-03-14 | 2005-04-05 | Autoliv Asp, Inc. | Anchoring attachment apparatus |
| WO2003002122A1 (en) | 2001-06-27 | 2003-01-09 | Elan Pharmaceuticals, Inc. | Beta-hydroxyamine derivatives useful in treatment of alzheimer's disease |
| US20040014678A1 (en) | 2001-08-08 | 2004-01-22 | Antonella Favit | Prevention of beta-amyloid neurotoxicity by blockade of the ubiquitin-proteasome proteolytoc pathway |
| WO2004083241A2 (en) | 2003-03-19 | 2004-09-30 | Takeda Pharmaceutical Company Limited | Btc-interacting proteins and use thereof |
| WO2006050475A2 (en) | 2004-11-03 | 2006-05-11 | Brigham And Women's Hospital, Inc. | Identification of dysregulated genes in patients with neurological diseases |
| CA2582270A1 (en) | 2004-11-15 | 2006-05-26 | Blanchette Rockefeller Neurosciences Institute | Abnormalities of phosphatase 2a (pp2a) for diagnosis and treatment of alzheimer's disease |
| US20090182021A1 (en) | 2005-08-03 | 2009-07-16 | Nanternet Philippe G | Tricyclic Beta-Secretase Inhibitors for the Treatment of Alzheimer's Disease |
| EP1934618B1 (en) | 2005-10-11 | 2009-05-13 | Blanchette Rockefeller Neurosciences Institute | Alzheimer's disease-specific alterations of the erk1/erk2 phosphorylation ratio-alzheimer's disease-specific molecular biomarkers (adsmb) |
| US20090029873A1 (en) | 2005-10-11 | 2009-01-29 | Blanchette Rockefeller Neurosciences Institute | Alzheimer's Disease-Specific Alterations of the Erk1/Erk2 Phosphorylation Ratio-Alzheimer's Disease-Specific Molecular Biomarkers (Adsmb) |
| US7595167B2 (en) | 2005-10-11 | 2009-09-29 | Blanchette Rockefeller Neurosciences Institute | Alzheimer's disease-specific alterations of the Erk1/Erk2 phosphorylation ratio |
| WO2007044094A1 (en) | 2005-10-11 | 2007-04-19 | Blanchette Rockefeller Neurosciences Institute | Alzheimer's disease-specific alterations of the erk1/erk2 phosphorylation ratio as alzheimer's disease-specific molecular biomarkers (adsmb) |
| WO2007043998A1 (en) | 2005-10-11 | 2007-04-19 | Blanchette Rockefeller Neurosciences Institute | Alzheimer’s disease-specific alterations of the erk1/erk2 phosphorylation ratio |
| JP2009541863A (ja) | 2006-06-21 | 2009-11-26 | レキシコル メディカル テクノロジー エルエルシー | 痴呆および痴呆型障害を分析および評価するためのシステムおよび方法 |
| JP2008143819A (ja) * | 2006-12-08 | 2008-06-26 | Tomoyuki Nishizaki | 酸化ストレス誘導細胞死の抑制剤 |
| KR20140049054A (ko) | 2007-02-09 | 2014-04-24 | 블랜체트 록펠러 뉴로사이언시즈 인스티튜트 | 두부 외상으로 유발된 기억 장애 및 뇌 손상에 대한 브리오스타틴, 브리오로그 및 기타 관련 물질의 치료학적 효과 |
| US20100209914A1 (en) | 2007-05-25 | 2010-08-19 | Ore Pharmaceuticals , Inc. | Methods, systems, and kits for evaluating multiple sclerosis |
| EP2767541A1 (en) * | 2008-03-03 | 2014-08-20 | Rxbio, Inc. | LPA receptor agonists and antagonists |
| EP3586839A1 (en) | 2008-07-28 | 2020-01-01 | Blanchette Rockefeller Neurosciences, Institute | Pkc-activating compounds for the treatment of neurodegenerative diseases |
-
2009
- 2009-07-28 EP EP19189948.3A patent/EP3586839A1/en not_active Withdrawn
- 2009-07-28 EP EP09790874.3A patent/EP2328572B1/en not_active Not-in-force
- 2009-07-28 CA CA2731171A patent/CA2731171C/en not_active Expired - Fee Related
- 2009-07-28 ES ES09790874.3T patent/ES2683021T3/es active Active
- 2009-07-28 US US12/510,681 patent/US8163800B2/en active Active
- 2009-07-28 WO PCT/US2009/051927 patent/WO2010014585A1/en not_active Ceased
- 2009-07-28 EP EP18172435.2A patent/EP3403650A3/en not_active Withdrawn
- 2009-07-28 CA CA2941035A patent/CA2941035A1/en not_active Abandoned
- 2009-07-28 JP JP2011521235A patent/JP5653917B2/ja not_active Expired - Fee Related
-
2012
- 2012-02-21 US US13/401,459 patent/US9119825B2/en active Active
-
2014
- 2014-09-08 JP JP2014182597A patent/JP2015042643A/ja active Pending
-
2015
- 2015-07-20 US US14/803,762 patent/US10323011B2/en active Active
-
2016
- 2016-03-15 JP JP2016051212A patent/JP6449186B2/ja not_active Expired - Fee Related
-
2018
- 2018-06-12 JP JP2018111869A patent/JP2018168170A/ja active Pending
-
2019
- 2019-05-01 US US16/400,132 patent/US10696644B2/en active Active
-
2020
- 2020-06-17 US US16/903,551 patent/US11390596B2/en active Active
-
2022
- 2022-07-06 US US17/858,204 patent/US11820745B2/en active Active
-
2023
- 2023-10-02 US US18/375,745 patent/US20240025870A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011529503A5 (enExample) | ||
| Darwesh et al. | Insights into the cardioprotective properties of n-3 PUFAs against ischemic heart disease via modulation of the innate immune system | |
| JP2020500193A5 (enExample) | ||
| Corminboeuf et al. | FPR2/ALXR agonists and the resolution of inflammation | |
| JP2014512351A5 (enExample) | ||
| CL2021000645A1 (es) | Métodos para reducir el riesgo de eventos cardiovasculares en un sujeto. | |
| JP2010196060A5 (enExample) | ||
| MX2021001906A (es) | Metodos para reducir la necesidad de revascularizacion arterial periferica en un sujeto tratado con estatinas. | |
| A Farooqui | n-3 fatty acid-derived lipid mediators in the brain: new weapons against oxidative stress and inflammation | |
| Auvin | Fatty acid oxidation and epilepsy | |
| JP2016538254A5 (enExample) | ||
| JP2017526623A5 (enExample) | ||
| JP2016501248A5 (enExample) | ||
| JP2007518764A5 (enExample) | ||
| RU2019110681A (ru) | Фармацевтическая композиция | |
| JP2016501249A5 (enExample) | ||
| CN106795452A (zh) | 含有二十碳五烯酸烷基酯的组合物及其制造方法 | |
| Salsinha et al. | The pro-and antiinflammatory activity of fatty acids | |
| Tanaka et al. | Metabolic conversion of C20 polymethylene-interrupted polyunsaturated fatty acids to essential fatty acids | |
| Rashid et al. | Role of polyunsaturated fatty acids and their metabolites on stem cell proliferation and differentiation | |
| Clarke et al. | Chain reactions: early-life stress alters the metabolic profile of plasma polyunsaturated fatty acids in adulthood | |
| JP2012513380A5 (enExample) | ||
| Das | Telomere length and polyunsaturated fatty acids | |
| JP2016523826A5 (enExample) | ||
| JP2014114256A5 (enExample) |